{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:50:21Z","timestamp":1792173021803,"version":"4.4.0"},"reference-count":24,"publisher":"Wiley","issue":"24","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) have elicited durable antitumor responses in multiple types of cancers. However, ICIs could also induce potential toxicities that involve all organs, including renal system. In this study, we aimed to conduct a comprehensive description of the ICIs\u2010induced renal toxicities and the potential effects of chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a pharmacovigilance study based on US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database between 01 January 2014 and 30 June 2019. Disproportionality analysis was used to assess the association between ICIs and renal adverse events (AEs), including reporting odds ratio (ROR) and information component (IC). ROR<jats:sub>025<\/jats:sub> and IC<jats:sub>025<\/jats:sub> are, respectively, 95% confidence interval lower end of ROR and IC. If the value of ROR<jats:sub>025<\/jats:sub> exceeding one or IC<jats:sub>025<\/jats:sub> higher than zero, then a signal was considered statistically significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 30,602,758 reports were extracted from the database, with 4578 reports for ICIs\u2010associated renal AEs. Renal AEs were more frequently reported in anti\u2010PD\u20101\/PD\u2010L1 versus anti\u2010CTLA\u20104\u00a0monotherapy group (ROR: 1.75, 95% CI: 1.52\u20132.01). Similarly, renal AEs were more commonly reported in ICIs polytherapy other than monotherapy group (ROR: 1.18, 95% CI: 1.10\u20131.27). Notably, ICIs plus chemotherapy strategies reported more renal toxicities compared to sole ICIs regimens (ROR: 1.30, 95% CI: 1.17\u20131.45), whereas exhibited lower fatality outcome rates. Importantly, acute kidney injury (1139, 24.88%) and renal failure (464, 10.14%) were the top two\u00a0most commonly reported ICIs\u2010associated renal AEs, and also observed with the top two\u00a0highest level of fatality outcome rates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A spectrum of renal AEs was detected in ICIs regimens and could be reinforced by ICIs combination. Compared to sole ICIs regimens, ICIs plus chemotherapy strategy reported more renal toxicities but lower fatality outcome rates. With the increasing popularity of ICIs especially combination strategies, it is vital important for clinicians to guarantee balance between durable clinical effects and potential renal toxicities in latest immunotherapy strategies.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.4343","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T16:37:23Z","timestamp":1638290243000},"page":"8754-8762","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database"],"prefix":"10.1002","volume":"10","author":[{"given":"Fangyuan","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Health Statistics Second Military Medical University Shanghai China"},{"name":"Department of Medical Service Naval Hospital of Eastern theater Zhoushan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghong","family":"Zhai","sequence":"additional","affiliation":[{"name":"Tongji University School of Medicine Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9069-9481","authenticated-orcid":false,"given":"Lei","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of health management Second Military Medical University Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jizhou","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Health Statistics Second Military Medical University Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Health Statistics Second Military Medical University Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Health Statistics Second Military Medical University Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Tongji University School of Medicine Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Health Statistics Second Military Medical University Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhai","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of health management Second Military Medical University Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Health Statistics Second Military Medical University Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2338-9501","authenticated-orcid":false,"given":"Jia","family":"He","sequence":"additional","affiliation":[{"name":"Department of Health Statistics Second Military Medical University Shanghai China"},{"name":"Tongji University School of Medicine Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30081-0"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32455-2"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01896"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.1848"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-016-0408-2"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.358"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0655-4"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000491631"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0764"},{"key":"e_1_2_10_15_1","unstructured":"U.S. Food and Drug Administration.Questions and Answers on FDA's Adverse Event Reporting System (FAERS).2019. Available at:https:\/\/www.fda.gov\/drugs\/surveillance\/fda\u2010adverse\u2010event\u2010reporting\u2010system\u2010faersAccessed September 1 2019"},{"key":"e_1_2_10_16_1","unstructured":"Maintenance and Support Services Organization [Homepage on the Internet].Support Documentation: MedDRA Version 22.0 EnglishMarch2018.https:\/\/www.meddra.org\/how\u2010to\u2010use\/support\u2010documentationAccessed September 1 2019."},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.668"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30608-9"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0617-x"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280211403604"},{"key":"e_1_2_10_21_1","first-page":"e212209","article-title":"Nivolumab plus ipilimumab vs nivolumab for previously treated patients with stage IV squamous cell lung cancer: the lung\u2010MAP S1400I phase 3 randomized clinical trial","volume":"15","author":"Gettinger SN","year":"2021","journal-title":"JAMA Oncol"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30230-0"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00276"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4343","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.4343","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T05:04:44Z","timestamp":1693199084000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.4343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":24,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1002\/cam4.4343"],"URL":"https:\/\/doi.org\/10.1002\/cam4.4343","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,29]]},"assertion":[{"value":"2021-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}